Carbidopa: Clinical Trials

26 trials of Carbidopa, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

19 completed, 2 terminated, 2 withdrawn, 1 active not recruiting. 26 Phase 2, 6 Phase 1, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 226Completed 19, Terminated 2, Withdrawn 2, Active not recruiting 1, Suspended 1, Unknown 1
Phase 16Completed 5, Terminated 1
Phase 33Active not recruiting 1, Completed 1, Suspended 1

Follow Carbidopa: new trials by email Literature Review of Carbidopa trials Research Report on Carbidopa

Trials (filtered) newest first · largest first

All 26 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Supplemental Open-Label Arm
Carbidopa 25 mg, Carbidopa-Levodopa 25/100 mg - Parkinsonian Signs in Older Persons
Phase 1 / Phase 2CompletedUniversity of Michigan52024-10-292026-04-14
Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Placebo-Controlled Arm
Carbidopa 25 mg, Carbidopa-Levodopa 25/100 mg, Placebo 1 - Parkinsonian Signs in Older Persons
Phase 1 / Phase 2CompletedUniversity of Michigan132024-03-152025-06-17
Histaminergic Basis of Fatigue in Multiple Sclerosis
L-Histidine, Placebo, Lodosyn - Multiple Sclerosis
Phase 2WithdrawnUniversity of Miami2022-01-012021-07-29
Assessing the Pharmacokinetics, Safety, Tolerability and Efficacy of Continuous Oral Levodopa Via the DopaFuse® Delivery System in Parkinson's Disease Patients
continuous oral delivery of levodopa/carbidopa - Parkinson's Disease
Phase 2CompletedSynAgile Corporation172021-06-162022-08-10
Dopaminergic Dysfunction in Late-Life Depression
L-Dopa, Placebo - Late Life Depression, Cognitive Decline
Phase 2CompletedVanderbilt University Medical Center792021-02-152026-08-06
Neurobiological Drivers of Mobility Resilience: The Dopaminergic System
carbidopa - Parkinsonian Signs in Older Persons
Phase 1 / Phase 2CompletedUniversity of Michigan142021-02-082024-04-04
Effects of 5HTP on the Injured Human Spinal Cord
5-Hydroxytryptophan 100 MG, 5-Hydroxytryptophan, Carbidopa - Spinal Cord Injuries
Phase 2 / Phase 3Active not recruitingUniversity of Alberta62020-07-012026-09-16
Transition From Acute to Chronic Back Pain : Effect of L-dopa,Gender,and Associated Brain Plasticity
carbidopa/levodopa and celecoxib, placebo1 and celecoxib, placebo1 and placebo2 - Chronic Back Pain
Phase 2WithdrawnSecond Affiliated Hospital of Wenzhou Medical University2019-10-012020-01-09
Effects of 5HTP and LDOPA on CNS Excitability After SCI
5HTP, L-DOPA, Placebo oral tablet - Spinal Cord Injuries
Phase 2 / Phase 3SuspendedJessica M D'Amico302019-06-192022-10-17
Study to Assess Pharmacokinetics of Accordion Pill Carbidopa-Levodopa Compared to Immediate Release Carbidopa-Levodopa in Parkinson's Disease Patients
Accordion Pill Carbidopa/Levodopa, Sinemet CR 25Mg-100Mg Extended-Release Tablet - Parkinson Disease
Phase 2UnknownIntec Pharma Ltd.122018-07-012018-07-05
Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off Reversal
Placebo, L-dopa 35 mg, L-dopa 70mg - Parkinson's Disease
Phase 2CompletedImpel Pharmaceuticals322018-05-082020-08-12
Carbidopa for the Treatment of Excessive Blood Pressure Variability
Carbidopa Low-Dose, Placebo, Carbidopa High-Dose - Dysautonomia, Familial, Baroreflex Failure Syndrome
Phase 2CompletedNYU Langone Health222015-09-012022-02-09
Antipsychotic Augmentation With L-Dopa
levodopa/carbidopa (generic version of Sinemet) - Schizophrenia
Phase 2CompletedCentre for Addiction and Mental Health132012-09-012016-03-15
Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" Episodes
CVT-301, Placebo, Sinemet (carbidopa/levodopa) - Idiopathic Parkinson's Disease
Phase 2CompletedAcorda Therapeutics252012-05-012017-07-27
Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease
ABT-SLV187, Oral Levodopa/Carbidopa, Infusion Pump: CADD-Legacy® 1400 Pump - Advanced Parkinson's Disease
Phase 2CompletedAbbVie (prior sponsor, Abbott)82011-10-012016-04-21
Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations
ODM-101 65mg Carbidopa, ODM-101 105mg Carbidopa, Stalevo - Parkinson's Disease
Phase 2CompletedOrion Corporation, Orion Pharma1172011-05-012013-11-21
Comparing Different Levodopa/Carbidopa/Entacapone Treatment Regimens
Carbidopa - Parkinson's Disease
Phase 2CompletedOrion Corporation, Orion Pharma272011-02-012011-09-12
A Safety, Tolerability and Pharmacokinetic Study of ND0611 on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Parkinson's Disease Patients
Saline, Carbidopa - Parkinson's Disease
Phase 1 / Phase 2CompletedNeuroDerm Ltd.242011-01-012011-12-06
A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease Subjects
XP21279 and carbidopa (experimental), Sinemet (comparator), Placebo for XP21279 and carbidopa - Parkinson's Disease
Phase 2CompletedXenoPort, Inc.352010-07-012021-02-18
An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects
Sinemet 25-100 Oral Tablet, XP21279, Carbidopa Pill - Parkinson's Disease
Phase 1 / Phase 2CompletedXenoPort, Inc.142009-05-012021-05-05

Showing 20 of 26. Sign in to see all of them.

Conditions studied

Parkinson Disease (12)  ·  Pain (2)  ·  Spinal Cord Injuries (2)  ·  Autonomic Nervous System Diseases (1)  ·  Cocaine-Related Disorders (1)  ·  Cognitive Dysfunction (1)  ·  Depressive Disorder, Major (1)  ·  Depressive Disorder, Treatment-Resistant (1)  ·  Dysautonomia, Familial (1)  ·  Dyskinesias (1)  ·  Fatigue (1)  ·  Fibromyalgia (1)  ·  Hypertension (1)  ·  Multiple Sclerosis (1)  ·  Multiple System Atrophy (1)

Sponsors

Orion Corporation, Orion Pharma (3)  ·  University of Michigan (3)  ·  XenoPort, Inc. (2)  ·  AbbVie (prior sponsor, Abbott) (1)  ·  Acorda Therapeutics (1)  ·  Centre for Addiction and Mental Health (1)  ·  Chelsea Therapeutics (1)  ·  Impel Pharmaceuticals (1)  ·  Intec Pharma Ltd. (1)  ·  Jessica M D'Amico (1)  ·  NYU Langone Health (1)  ·  National Institute of Neurological Disorders and Stroke (NINDS) (1)  ·  NeuroDerm Ltd. (1)  ·  Oregon Health and Science University (1)  ·  Second Affiliated Hospital of Wenzhou Medical University (1)

Countries

United States (14)  ·  Canada (2)  ·  Finland (2)  ·  Israel (2)  ·  United Kingdom (2)  ·  Australia (1)  ·  China (1)  ·  Italy (1)  ·  Luxembourg (1)  ·  Serbia (1)  ·  Spain (1)  ·  Sweden (1)

Top investigators

Chatkaew Pongmala, PhD (2)  ·  Jessica D'Amico, PhD (2)  ·  Alfredo J Gamboa, MD (1)  ·  BinBin Wu, doctor (1)  ·  Claudia Trenkwalder, MD (1)  ·  Dan Chen, M.D. (1)  ·  David S Goldstein, M.D. (1)  ·  Ephraim Heller, MBA (1)  ·  Ernest Choy, M.D. (1)  ·  Gary Remington, MD PhD FRCPC (1)  ·  Horacio C Kaufmann, MD (1)  ·  John G Nutt, MD (1)  ·  John Grabowski, PhD (1)  ·  Juha Rinne, Dr (1)  ·  Kottil Rammohan, MD (1)

Results publications

PMID 30824559, PMID 38698639

NIH funding

U01AG061393 (3), 2018 (1), P50DA009262 (1)